NO20100307L - GLP-1 analoger - Google Patents
GLP-1 analogerInfo
- Publication number
- NO20100307L NO20100307L NO20100307A NO20100307A NO20100307L NO 20100307 L NO20100307 L NO 20100307L NO 20100307 A NO20100307 A NO 20100307A NO 20100307 A NO20100307 A NO 20100307A NO 20100307 L NO20100307 L NO 20100307L
- Authority
- NO
- Norway
- Prior art keywords
- analogs
- glp
- analogues
- peptide
- glucagon
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Det er beskrevet peptidanaloger av glukagon-lignende peptid-1, farmasøytisk akseptable salter derav, fremgangsmåte for anvendelse av slike analoger for behandling av pattedyr og farmasøytiske sammensetninger nyttige for dette og som derfor omfatter nevnte analoger.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11118698P | 1998-12-07 | 1998-12-07 | |
US20683398A | 1998-12-07 | 1998-12-07 | |
PCT/US1999/028929 WO2000034332A1 (en) | 1998-12-07 | 1999-12-07 | Glp-1 analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20100307L true NO20100307L (no) | 2001-08-06 |
Family
ID=26808707
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20012787A NO330293B1 (no) | 1998-12-07 | 2001-06-06 | GLP-1 analoger samt anvendelse derav og farmasoytisk sammensetning |
NO20100307A NO20100307L (no) | 1998-12-07 | 2010-03-04 | GLP-1 analoger |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20012787A NO330293B1 (no) | 1998-12-07 | 2001-06-06 | GLP-1 analoger samt anvendelse derav og farmasoytisk sammensetning |
Country Status (21)
Country | Link |
---|---|
US (2) | US7368427B1 (no) |
EP (2) | EP1137666B9 (no) |
JP (3) | JP2002538081A (no) |
KR (1) | KR100458748B1 (no) |
CN (2) | CN100334109C (no) |
AT (1) | ATE394423T1 (no) |
AU (1) | AU770609B2 (no) |
BR (1) | BR9916027A (no) |
CA (1) | CA2352573C (no) |
CZ (2) | CZ303120B6 (no) |
DE (1) | DE69938669D1 (no) |
DK (1) | DK1137666T5 (no) |
ES (1) | ES2302390T3 (no) |
HU (1) | HUP0104579A3 (no) |
IL (2) | IL143481A0 (no) |
NO (2) | NO330293B1 (no) |
PL (3) | PL205713B1 (no) |
PT (1) | PT1137666E (no) |
RU (1) | RU2208015C2 (no) |
TW (2) | TWI262925B (no) |
WO (1) | WO2000034332A1 (no) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322545A1 (en) | 1998-12-07 | 2011-05-18 | Ipsen Pharma | Analogues of GLP-1 |
KR100458748B1 (ko) * | 1998-12-07 | 2004-12-03 | 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 | Glp-1 유사체 |
JP2004509079A (ja) * | 2000-08-02 | 2004-03-25 | セラテクノロジーズ・インコーポレーテッド | 効力が増大した修飾生体ペプチド |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
EP1326630B1 (en) | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Use of glp-2 peptides |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US6894024B2 (en) * | 2000-10-20 | 2005-05-17 | Amylin Pharmaceuticals, Inc. | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
EP1346722B1 (en) | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
EP2022505B1 (en) * | 2001-07-31 | 2011-12-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
AU2012202081B2 (en) * | 2001-07-31 | 2014-09-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 Exendin-4 peptide analogs and uses thereof |
JP2005514337A (ja) * | 2001-10-18 | 2005-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | ヒトグルカゴン様ペプチド−1模倣体、並びに糖尿病および関連疾患の処置におけるその使用 |
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
WO2004009616A2 (en) * | 2002-07-23 | 2004-01-29 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Ghrelin analogs |
EP1583549A4 (en) * | 2003-01-17 | 2006-10-04 | Sod Conseils Rech Applic | YY PEPTIDE ANALOGS |
DE602004025205D1 (de) * | 2003-02-19 | 2010-03-11 | Ipsen Pharma | Glp-1-analoga |
JP4543236B2 (ja) * | 2003-03-28 | 2010-09-15 | 独立行政法人農業生物資源研究所 | 組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質 |
US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (de) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
EP2210900A3 (en) * | 2003-12-16 | 2010-08-11 | Ipsen Pharma | Analogues of GLP-1 |
TWI353250B (en) * | 2003-12-16 | 2011-12-01 | Ipsen Pharma Sas | Glp-1 pharmaceutical compositions |
AU2005203925A1 (en) | 2004-01-08 | 2005-07-21 | Theratechnologies Inc. | Glucagon-Like Peptide-1 analogs with long duration of action |
TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
JP2008543816A (ja) * | 2005-06-13 | 2008-12-04 | インペリアル イノベーションズ リミテッド | 新規化合物および該化合物が摂食行動に及ぼす効果 |
WO2007051987A1 (en) * | 2005-11-01 | 2007-05-10 | Activotec Spp Limited | Insulinotropic compounds and uses thereof |
WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
CA2648936C (en) | 2006-04-20 | 2013-07-09 | Amgen Inc. | Glp-1 compounds |
EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US8669228B2 (en) * | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
JP2010538069A (ja) * | 2007-09-07 | 2010-12-09 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | エキセンディン−4およびエキセンディン−3の類似体 |
CN102088989B (zh) * | 2008-06-17 | 2014-11-26 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
WO2010076809A2 (en) * | 2008-12-29 | 2010-07-08 | Panacea Biotec Ltd | Glp-1 analogs and uses thereof |
RU2580317C2 (ru) * | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
KR20140107340A (ko) | 2011-12-12 | 2014-09-04 | 레셉토스, 인코포레이티드 | 당뇨병과 같은 치료를 위한 glp-1 수용체 조절제로서 작용하는 4 개의 사이클을 포함하는 카르복실산 유도체 |
CN102584982B (zh) * | 2012-02-10 | 2014-02-05 | 深圳翰宇药业股份有限公司 | 一种纯化固相合成利拉鲁肽粗肽的方法 |
US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
SI3004155T1 (sl) | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
CN103285379A (zh) * | 2013-06-09 | 2013-09-11 | 南方医科大学 | Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途 |
EP3008056B8 (en) | 2013-06-11 | 2021-03-03 | Receptos Llc | Novel glp-1 receptor modulators |
CA2955836C (en) | 2014-07-25 | 2023-02-14 | Celgene International Ii Sarl | Glp-1 receptor modulators |
JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
CA2969944A1 (en) | 2014-12-10 | 2016-06-16 | Celgene International Ii Sarl | Glp-1 receptor modulators |
BR112017019170A2 (pt) | 2015-03-09 | 2018-07-10 | Intekrin Therapeutics, Inc. | métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia |
SG11201805255TA (en) | 2015-12-23 | 2018-07-30 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
AU2016379403B2 (en) | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
JP2019520336A (ja) | 2016-06-02 | 2019-07-18 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 水溶性で化学的に安定なグルカゴンペプチド |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのPPARγアゴニスト |
CN109942696A (zh) * | 2017-12-21 | 2019-06-28 | 中国药科大学 | 长效化胰高血糖素样肽-1(glp-1)类似物及其应用 |
CN116970062B (zh) * | 2022-04-29 | 2024-04-09 | 南京知和医药科技有限公司 | 一种超长效glp-1多肽衍生物及其制备方法和用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1539498A (en) | 1925-05-26 | And fifteen | ||
CA2073856C (en) * | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
JP2575298B2 (ja) * | 1992-06-15 | 1997-01-22 | フアイザー・インコーポレイテツド | グルカゴン様ペプチド及びインシュリノトロピン誘導体 |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
EP0879279A4 (en) * | 1996-02-06 | 2000-07-12 | Lilly Co Eli | DIABETE TREATMENT |
DE69737479T4 (de) * | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
WO1998043658A1 (en) * | 1997-03-31 | 1998-10-08 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
EP1056774A1 (en) | 1998-02-27 | 2000-12-06 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
KR100458748B1 (ko) | 1998-12-07 | 2004-12-03 | 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 | Glp-1 유사체 |
EP2322545A1 (en) | 1998-12-07 | 2011-05-18 | Ipsen Pharma | Analogues of GLP-1 |
WO2001035988A1 (en) | 1999-11-12 | 2001-05-25 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
-
1999
- 1999-12-07 KR KR10-2001-7007050A patent/KR100458748B1/ko not_active IP Right Cessation
- 1999-12-07 DK DK99960657T patent/DK1137666T5/da active
- 1999-12-07 CN CNB998141852A patent/CN100334109C/zh not_active Expired - Fee Related
- 1999-12-07 ES ES99960657T patent/ES2302390T3/es not_active Expired - Lifetime
- 1999-12-07 PL PL349609A patent/PL205713B1/pl unknown
- 1999-12-07 CZ CZ20011895A patent/CZ303120B6/cs not_active IP Right Cessation
- 1999-12-07 IL IL14348199A patent/IL143481A0/xx unknown
- 1999-12-07 AT AT99960657T patent/ATE394423T1/de active
- 1999-12-07 CZ CZ20120110A patent/CZ303399B6/cs not_active IP Right Cessation
- 1999-12-07 CN CN2007101410499A patent/CN101108878B/zh not_active Expired - Fee Related
- 1999-12-07 PL PL385112A patent/PL208751B1/pl unknown
- 1999-12-07 DE DE69938669T patent/DE69938669D1/de not_active Expired - Lifetime
- 1999-12-07 EP EP99960657A patent/EP1137666B9/en not_active Expired - Lifetime
- 1999-12-07 CA CA2352573A patent/CA2352573C/en not_active Expired - Fee Related
- 1999-12-07 US US09/856,676 patent/US7368427B1/en not_active Expired - Fee Related
- 1999-12-07 RU RU2001118839/04A patent/RU2208015C2/ru not_active IP Right Cessation
- 1999-12-07 EP EP08005960A patent/EP1992641A3/en not_active Withdrawn
- 1999-12-07 BR BR9916027-7A patent/BR9916027A/pt not_active IP Right Cessation
- 1999-12-07 JP JP2000586774A patent/JP2002538081A/ja active Pending
- 1999-12-07 PL PL393611A patent/PL393611A1/pl unknown
- 1999-12-07 AU AU17512/00A patent/AU770609B2/en not_active Ceased
- 1999-12-07 PT PT99960657T patent/PT1137666E/pt unknown
- 1999-12-07 WO PCT/US1999/028929 patent/WO2000034332A1/en active Application Filing
- 1999-12-07 HU HU0104579A patent/HUP0104579A3/hu unknown
-
2000
- 2000-01-07 TW TW088121393A patent/TWI262925B/zh not_active IP Right Cessation
- 2000-01-07 TW TW095106593A patent/TWI339208B/zh not_active IP Right Cessation
-
2001
- 2001-05-31 IL IL143481A patent/IL143481A/en not_active IP Right Cessation
- 2001-06-06 NO NO20012787A patent/NO330293B1/no not_active IP Right Cessation
-
2005
- 2005-10-13 JP JP2005298418A patent/JP2006077022A/ja active Pending
-
2008
- 2008-05-06 US US12/115,976 patent/US20090149378A1/en not_active Abandoned
-
2009
- 2009-08-14 JP JP2009188046A patent/JP2010001301A/ja active Pending
-
2010
- 2010-03-04 NO NO20100307A patent/NO20100307L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20100307L (no) | GLP-1 analoger | |
DE69922043D1 (de) | Glp-1 analoge | |
MXPA02012203A (es) | Analogos de peptido 1 tipo glucagon. | |
MX9704439A (es) | Derivados heterociclicos aromaticos como inhibidores de enzima. | |
BR0212080A (pt) | composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1 | |
NO2010012I1 (no) | Exennatid (Eksenatid) | |
CO5090908A1 (es) | Procedimiento para administrar peptidos insulinotropicos | |
BG104089A (en) | Dolastatine 15 derivatives | |
WO2004074315A3 (en) | Analogues of glp-1 | |
NO20080552L (no) | GLP-1 farmasoytiske sammensetninger | |
DE59308848D1 (de) | Anwendung von urodilatin bei lungen- und bronchialerkrankungen | |
EP2210900A3 (en) | Analogues of GLP-1 | |
MY128529A (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
EP1359159A3 (en) | Analogues of GLP-1 | |
DK1090028T3 (da) | Umættede 14,15-cyclopropano-androstaner, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser | |
UA88862C2 (en) | Glucagon-like peptide-1 analogs | |
HK1045253A1 (en) | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis | |
MX9702532A (es) | Composiciones farmaceuticas para el tratamiento de la rinitis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |